[{"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125-001", "question": "A 54-year-old man with decompensated alcoholic cirrhosis (MELD-Na 29) is intubated for acute variceal hemorrhage and started on norepinephrine for hemorrhagic shock. Despite volume resuscitation, blood products, and endoscopic band ligation, he requires increasing vasopressor doses. Continuous renal replacement therapy is initiated for worsening azotemia and hyperkalemia. His MAP is 62 mm Hg on norepinephrine 0.24 mcg/kg/min and vasopressin 0.03 units/min. Lactate is 5.1 mmol/L; pH 7.28; ScvO2 76%. Bedside echo shows hyperdynamic LV function, small underfilled LV, and collapsible IVC. CVP is 4 mm Hg. You are considering adding a third agent. Which vasopressor strategy is most appropriate now?", "options": ["Add epinephrine infusion targeting higher MAP (70-75 mm Hg)", "Add low-dose dobutamine to improve splanchnic perfusion", "Add angiotensin II infusion while maintaining current MAP target", "Increase vasopressin above 0.04 units/min to exploit V1 receptor effect", "Switch norepinephrine to phenylephrine to minimize beta-adrenergic effects"], "answer": "C", "answer_index": 2, "explanation": "He has vasodilatory shock in advanced cirrhosis with catecholamine-resistant hypotension despite adequate volume; angiotensin II is reasonable as a third-line agent in catecholamine-refractory vasodilatory shock and has emerging use in hepatorenal-type circulatory failure. Epinephrine would increase lactate and myocardial oxygen demand without addressing RAAS dysregulation; high-dose vasopressin increases ischemia risk, phenylephrine may worsen gut perfusion, and dobutamine is not indicated with hyperdynamic LV and adequate ScvO2.", "generator_model": "gpt-5.1-2025-11-13", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Decompensated alcoholic cirrhosis with high MELD-Na; variceal bleed with ongoing vasodilatory/ distributive shock after control of bleeding; hyperdynamic, underfilled LV, low CVP, collapsible IVC (hypovolemia/vasodilation), high ScvO2, elevated lactate; already on moderate-dose norepinephrine plus standard-dose vasopressin. This represents catecholamine-refractory vasodilatory shock in advanced cirrhosis/possible hepatorenal-type physiology.\\nAngiotensin II (C) is consistent with evidence for third-line use in catecholamine-resistant vasodilatory shock, including cirrhosis-associated vasoplegia and hepatorenal physiology. Epinephrine (A) would raise lactate and myocardial O2 demand without targeting RAAS dysregulation and is not preferred. Dobutamine (B) is inappropriate with hyperdynamic LV and adequate ScvO2, suggesting no low-output component. Increasing vasopressin above 0.04 units/min (D) exceeds commonly accepted upper dosing limits and increases ischemic risk. Switching to phenylephrine (E) is generally inferior to norepinephrine in septic/vasodilatory shock and may worsen splanchnic perfusion.\\nMain medical accuracy issues: Minor—angiotensin II’s use in cirrhotic vasoplegia is “emerging” but within contemporary, defensible practice. \\nMinimal fix: Clarify explicitly that he has persistent vasodilatory shock despite adequate volume resuscitation and optimal norepinephrine/vasopressin to emphasize catecholamine-refractory status and justify third-line angiotensin II use.\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Decompensated alcoholic cirrhosis with high MELD-Na; variceal bleed with ongoing vasodilatory/ distributive shock after control of bleeding; hyperdynamic, underfilled LV, low CVP, collapsible IVC (hypovolemia/vasodilation), high ScvO2, elevated lactate; already on moderate-dose norepinephrine plus standard-dose vasopressin. This represents catecholamine-refractory vasodilatory shock in advanced cirrhosis/possible hepatorenal-type physiology.\nAngiotensin II (C) is consistent with evidence for third-line use in catecholamine-resistant vasodilatory shock, including cirrhosis-associated vasoplegia and hepatorenal physiology. Epinephrine (A) would raise lactate and myocardial O2 demand without targeting RAAS dysregulation and is not preferred. Dobutamine (B) is inappropriate with hyperdynamic LV and adequate ScvO2, suggesting no low-output component. Increasing vasopressin above 0.04 units/min (D) exceeds commonly accepted upper dosing limits and increases ischemic risk. Switching to phenylephrine (E) is generally inferior to norepinephrine in septic/vasodilatory shock and may worsen splanchnic perfusion.\nMain medical accuracy issues: Minor—angiotensin II’s use in cirrhotic vasoplegia is “emerging” but within contemporary, defensible practice. \nMinimal fix: Clarify explicitly that he has persistent vasodilatory shock despite adequate volume resuscitation and optimal norepinephrine/vasopressin to emphasize catecholamine-refractory status and justify third-line angiotensin II use.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125-002", "question": "A 63-year-old woman with a history of JAK2-positive polycythemia vera treated with hydroxyurea for 9 years presents with 3 months of progressive fatigue, 7-kg weight loss, early satiety, and drenching night sweats. Exam shows marked splenomegaly 12 cm below the costal margin. CBC: Hgb 9.1 g/dL, MCV 96 fL, WBC 18,000/µL with left shift, platelets 110,000/µL. Peripheral smear reveals tear-drop cells, nucleated RBCs, and leukoerythroblastosis. LDH is elevated; uric acid is high. Bone marrow aspirate is 'dry'; core biopsy shows hypercellular marrow with grade 3 reticulin fibrosis and atypical megakaryocytic clusters. Cytogenetics: new complex karyotype with monosomy 7. Which is the most appropriate next step in disease-directed management?", "options": ["Escalate hydroxyurea dose and add low-dose aspirin", "Start ruxolitinib and defer further planning until spleen size stabilizes", "Proceed to allogeneic hematopoietic stem cell transplantation evaluation", "Begin azacitidine as first-line therapy for post-PV myelofibrosis", "Initiate weekly pegylated interferon alfa-2a for cytoreduction"], "answer": "C", "answer_index": 2, "explanation": "She has post-polycythemia vera myelofibrosis with symptomatic splenomegaly, cytopenias, leukoerythroblastosis, and high-risk features (complex karyotype, monosomy 7), making allogeneic stem cell transplantation the only curative option and the preferred strategy if eligible. Ruxolitinib improves symptoms and spleen size but is not curative; azacitidine and interferon are not standard first-line disease-modifying therapies in high-risk post-PV MF, and hydroxyurea escalation will not address progression.", "generator_model": "gpt-5.1-2025-11-13", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Long-standing JAK2+ polycythemia vera on hydroxyurea now with weight loss, night sweats, marked splenomegaly, anemia, thrombocytopenia, leukoerythroblastosis, tear-drop cells, dry tap with grade 3 reticulin fibrosis and atypical megakaryocytes, plus new complex karyotype with monosomy 7. These establish post-PV myelofibrosis with high-risk disease (adverse cytogenetics, symptomatic, cytopenias), where allogeneic HSCT is the only curative, guideline-preferred option for eligible patients.\\nOption C (HSCT evaluation) fits current standards: in high-risk MF (including post-PV) in a transplant-eligible 63-year-old, referral for allogeneic transplant is recommended. Ruxolitinib (B) is appropriate for symptom/spleen control but is not curative and is generally used as bridge, not instead of transplant planning. A (escalating hydroxyurea) ignores clear progression to MF. D (azacitidine) and E (pegylated interferon) are not standard first-line disease-directed therapies in high-risk post-PV MF.\\nMain medical accuracy issues: Minor—item simplifies nuanced sequencing (e.g., ruxolitinib as bridge), but does not mislead regarding the key teaching that HSCT is the definitive disease-directed therapy.\\nMinimal fix: Explicitly state transplant eligibility (e.g., good performance status, limited comorbidities) to remove any ambiguity about proceeding to HSCT evaluation.\\n\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Long-standing JAK2+ polycythemia vera on hydroxyurea now with weight loss, night sweats, marked splenomegaly, anemia, thrombocytopenia, leukoerythroblastosis, tear-drop cells, dry tap with grade 3 reticulin fibrosis and atypical megakaryocytes, plus new complex karyotype with monosomy 7. These establish post-PV myelofibrosis with high-risk disease (adverse cytogenetics, symptomatic, cytopenias), where allogeneic HSCT is the only curative, guideline-preferred option for eligible patients.\nOption C (HSCT evaluation) fits current standards: in high-risk MF (including post-PV) in a transplant-eligible 63-year-old, referral for allogeneic transplant is recommended. Ruxolitinib (B) is appropriate for symptom/spleen control but is not curative and is generally used as bridge, not instead of transplant planning. A (escalating hydroxyurea) ignores clear progression to MF. D (azacitidine) and E (pegylated interferon) are not standard first-line disease-directed therapies in high-risk post-PV MF.\nMain medical accuracy issues: Minor—item simplifies nuanced sequencing (e.g., ruxolitinib as bridge), but does not mislead regarding the key teaching that HSCT is the definitive disease-directed therapy.\nMinimal fix: Explicitly state transplant eligibility (e.g., good performance status, limited comorbidities) to remove any ambiguity about proceeding to HSCT evaluation.\n", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125-003", "question": "A 28-year-old G1P0 woman at 33 weeks' gestation presents to the ED with acute dyspnea, pleuritic chest pain, and near syncope. HR 132/min, BP 82/48 mm Hg, RR 30/min, SpO2 89% on 6 L nasal cannula. Bedside echo reveals a dilated RV with McConnell sign and septal flattening. CTA is unavailable; lower-extremity duplex is pending. She is consentable and has no contraindications to thrombolysis. Fetal heart tones are 150 bpm with moderate variability. Which management is most appropriate now?", "options": ["Systemic thrombolysis with weight-based alteplase bolus and infusion", "Urgent catheter-directed thrombolysis with reduced-dose alteplase", "Immediate transfer for surgical embolectomy with cardiopulmonary bypass", "Initiate high-dose unfractionated heparin and defer reperfusion until postpartum", "Administer tenecteplase as a single IV bolus followed by heparin"], "answer": "A", "answer_index": 0, "explanation": "She has high-risk (massive) pulmonary embolism with shock in late pregnancy; systemic thrombolysis is recommended when no absolute contraindications exist, as maternal survival takes priority and pregnancy is only a relative contraindication. Catheter-directed therapy or surgical embolectomy may be considered when thrombolysis is contraindicated or fails, not as first-line; deferring reperfusion is unsafe, and tenecteplase bolus lacks robust pregnancy-specific safety and dosing data compared with standard alteplase protocols.", "generator_model": "gpt-5.1-2025-11-13", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: 33-week pregnant patient with acute dyspnea, pleuritic chest pain, hypotension (BP 82/48), tachycardia, hypoxemia, and bedside echo showing RV dilation, McConnell sign, septal flattening → high‑risk (massive) PE with obstructive shock. CTA unavailable, duplex pending, but echo plus hemodynamic collapse is sufficient for emergent reperfusion. She is consentable, late third trimester, and has no thrombolysis contraindications.\\nSystemic thrombolysis with standard weight-based alteplase (A) is guideline‑recommended first‑line for massive PE with shock when no absolute contraindications exist; pregnancy is a relative, not absolute, contraindication, and maternal survival takes priority. Catheter‑directed thrombolysis (B) and surgical embolectomy (C) are options when lysis is contraindicated or fails, not first‑line. Deferring reperfusion with heparin alone (D) is unsafe in shock. Tenecteplase bolus (E) is not guideline‑standard for PE in pregnancy and has less evidence than alteplase.\\nMain medical issues: Minor—some centers increasingly use TNK for PE generally, but pregnancy data remain limited, so A is still clearly best supported. \\nMinimal fix: Cite or imply that institutional resources for catheter/surgical options are available but still second‑line to systemic lysis in this setting, to reinforce hierarchy of choices.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: 33-week pregnant patient with acute dyspnea, pleuritic chest pain, hypotension (BP 82/48), tachycardia, hypoxemia, and bedside echo showing RV dilation, McConnell sign, septal flattening → high‑risk (massive) PE with obstructive shock. CTA unavailable, duplex pending, but echo plus hemodynamic collapse is sufficient for emergent reperfusion. She is consentable, late third trimester, and has no thrombolysis contraindications.\nSystemic thrombolysis with standard weight-based alteplase (A) is guideline‑recommended first‑line for massive PE with shock when no absolute contraindications exist; pregnancy is a relative, not absolute, contraindication, and maternal survival takes priority. Catheter‑directed thrombolysis (B) and surgical embolectomy (C) are options when lysis is contraindicated or fails, not first‑line. Deferring reperfusion with heparin alone (D) is unsafe in shock. Tenecteplase bolus (E) is not guideline‑standard for PE in pregnancy and has less evidence than alteplase.\nMain medical issues: Minor—some centers increasingly use TNK for PE generally, but pregnancy data remain limited, so A is still clearly best supported. \nMinimal fix: Cite or imply that institutional resources for catheter/surgical options are available but still second‑line to systemic lysis in this setting, to reinforce hierarchy of choices.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125-004", "question": "A 4-year-old boy is brought to the PICU with progressive leg weakness and refusal to walk for 5 days after a viral upper respiratory infection. Exam: flaccid symmetric weakness in legs > arms, areflexia, intact sensation, no bowel/bladder dysfunction, and no cranial nerve involvement. He can lift his head briefly but cannot stand; FVC is 55% predicted. MRI spine is normal. CSF shows protein 42 mg/dL, 3 WBC/µL. Nerve conduction studies show reduced CMAP amplitudes with preserved conduction velocities and distal latencies; sensory studies are normal, and F-waves are absent. Which subtype best describes his neuropathy and has implications for prognosis and treatment response?", "options": ["Acute inflammatory demyelinating polyradiculoneuropathy (AIDP)", "Acute motor axonal neuropathy (AMAN) variant of Guillain-Barré syndrome", "Acute motor and sensory axonal neuropathy (AMSAN)", "Miller Fisher syndrome", "Acute flaccid myelitis related to enterovirus D68"], "answer": "B", "answer_index": 1, "explanation": "Normal conduction velocities with low CMAP amplitudes, preserved sensory responses, and absent F-waves indicate a purely motor axonal process, characteristic of AMAN, which in children often follows infection and may have rapid progression but good recovery with immunotherapy. AIDP would show demyelinating features (slowed velocities, prolonged latencies), AMSAN would have sensory involvement, Miller Fisher presents with ophthalmoplegia/ataxia, and acute flaccid myelitis involves spinal gray matter with MRI abnormalities and asymmetric weakness.", "generator_model": "gpt-5.1-2025-11-13", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Child with acute, symmetric, flaccid, areflexic weakness after URI; sensation intact; no bowel/bladder or cranial nerve deficits; CSF protein not yet elevated (early GBS possible); MRI spine normal. Nerve conduction: reduced CMAP amplitudes with normal conduction velocities/distal latencies, normal sensory responses, and absent F-waves. These findings indicate a purely motor axonal neuropathy consistent with acute motor axonal neuropathy (AMAN) variant of Guillain‑Barré.\\nAlternative choices: AIDP (A) would require demyelinating features—slowed velocities, prolonged distal latencies, conduction block—which are specifically absent. AMSAN (C) should have sensory NCS abnormalities, which are explicitly normal. Miller Fisher (D) is characterized by ophthalmoplegia, ataxia, and areflexia, none present. Acute flaccid myelitis (E) would show asymmetric weakness, LMN signs with spinal gray matter lesions on MRI—spine MRI here is normal and weakness symmetric.\\nLogical issues: None; clues clearly discriminate AMAN from other options.\\nMedical accuracy: Description of electrodiagnostic patterns for AMAN vs AIDP/AMSAN, and clinical distinctions from Miller Fisher and acute flaccid myelitis, are accurate and contemporary.\\nMinimal fix: None required; item is already clear and board-appropriate. Optionally, specify timing of CSF (e.g., “on day 5”) to reinforce early normal protein in GBS variants.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Child with acute, symmetric, flaccid, areflexic weakness after URI; sensation intact; no bowel/bladder or cranial nerve deficits; CSF protein not yet elevated (early GBS possible); MRI spine normal. Nerve conduction: reduced CMAP amplitudes with normal conduction velocities/distal latencies, normal sensory responses, and absent F-waves. These findings indicate a purely motor axonal neuropathy consistent with acute motor axonal neuropathy (AMAN) variant of Guillain‑Barré.\nAlternative choices: AIDP (A) would require demyelinating features—slowed velocities, prolonged distal latencies, conduction block—which are specifically absent. AMSAN (C) should have sensory NCS abnormalities, which are explicitly normal. Miller Fisher (D) is characterized by ophthalmoplegia, ataxia, and areflexia, none present. Acute flaccid myelitis (E) would show asymmetric weakness, LMN signs with spinal gray matter lesions on MRI—spine MRI here is normal and weakness symmetric.\nLogical issues: None; clues clearly discriminate AMAN from other options.\nMedical accuracy: Description of electrodiagnostic patterns for AMAN vs AIDP/AMSAN, and clinical distinctions from Miller Fisher and acute flaccid myelitis, are accurate and contemporary.\nMinimal fix: None required; item is already clear and board-appropriate. Optionally, specify timing of CSF (e.g., “on day 5”) to reinforce early normal protein in GBS variants.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125-005", "question": "A 47-year-old man with poorly controlled type 2 diabetes and daily alcohol use presents with 10 days of fever, right-sided headache, and progressive confusion. He was treated with oral amoxicillin-clavulanate for presumed sinusitis without improvement. On exam he is disoriented, febrile (38.8°C), with mild left hemiparesis and papilledema. CT head with contrast shows a 3.5-cm ring-enhancing lesion in the right frontal lobe with extensive surrounding edema contiguous with opacified frontal sinus. Emergent dexamethasone and broad-spectrum IV antibiotics are started. Neurocritical care team plans operative management. Which surgical approach is most appropriate now?", "options": ["CT-guided stereotactic needle aspiration of the abscess", "Open craniotomy with complete abscess excision and sinus drainage", "Endoscopic transnasal drainage of the frontal sinus only", "Placement of an external ventricular drain for CSF diversion and observation", "Delay surgical intervention; continue maximal medical therapy for 2 weeks"], "answer": "B", "answer_index": 1, "explanation": "A large frontal lobe abscess contiguous with frontal sinus and mass effect in an immunocompromised host favors open craniotomy with abscess excision plus definitive sinus drainage to eradicate the source and relieve mass effect. Needle aspiration alone risks persistent infection from ongoing sinus seeding; sinus drainage only is insufficient; EVD does not address the mass; delaying surgery risks herniation and neurological decline.", "generator_model": "gpt-5.1-2025-11-13", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: 3.5‑cm ring-enhancing frontal lobe lesion contiguous with opacified frontal sinus; extensive edema and papilledema (mass effect); focal deficit (left hemiparesis); immunocompromised host (poorly controlled diabetes, daily alcohol); failure of prior oral antibiotics; neurocritical care team planning operative management.\\nMost likely diagnosis is a sizable frontal brain abscess from direct spread of sinusitis with significant mass effect and a persistent extracranial source of infection. In this setting, standard neurosurgical teaching favors open craniotomy with abscess excision plus definitive frontal sinus drainage to both relieve mass effect and eradicate the contiguous focus, making B the best option.\\nA (stereotactic aspiration) is generally preferred for deep, multiple, or high‑risk locations but would leave the infected sinus source unaddressed. C (sinus drainage only) ignores the intracranial abscess. D (EVD) addresses ICP but not the mass lesion or infection. E (delay surgery) is unsafe given mass effect and neurologic decline.\\nMain medical accuracy issues: none significant; management reasoning is contemporary and appropriate. \\nMinimal fix: Explicitly state “large superficial frontal lobe abscess adjacent to the skull” to further justify craniotomy over aspiration for learners.\\n\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: 3.5‑cm ring-enhancing frontal lobe lesion contiguous with opacified frontal sinus; extensive edema and papilledema (mass effect); focal deficit (left hemiparesis); immunocompromised host (poorly controlled diabetes, daily alcohol); failure of prior oral antibiotics; neurocritical care team planning operative management.\nMost likely diagnosis is a sizable frontal brain abscess from direct spread of sinusitis with significant mass effect and a persistent extracranial source of infection. In this setting, standard neurosurgical teaching favors open craniotomy with abscess excision plus definitive frontal sinus drainage to both relieve mass effect and eradicate the contiguous focus, making B the best option.\nA (stereotactic aspiration) is generally preferred for deep, multiple, or high‑risk locations but would leave the infected sinus source unaddressed. C (sinus drainage only) ignores the intracranial abscess. D (EVD) addresses ICP but not the mass lesion or infection. E (delay surgery) is unsafe given mass effect and neurologic decline.\nMain medical accuracy issues: none significant; management reasoning is contemporary and appropriate. \nMinimal fix: Explicitly state “large superficial frontal lobe abscess adjacent to the skull” to further justify craniotomy over aspiration for learners.\n", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125-006", "question": "A 66-year-old man with COPD and metastatic non-small cell lung cancer (PD-L1 80%) started pembrolizumab 10 weeks ago. He presents with 4 days of worsening exertional dyspnea and dry cough, afebrile, with O2 saturation 90% on room air. CT pulmonary angiography shows no embolus but reveals new bilateral, patchy ground-glass opacities and reticular changes in the lower lobes with subpleural sparing. There is no infection on extensive workup, BNP is normal, and no cardiac ischemia. He is on no new drugs besides pembrolizumab. How should this complication be graded and managed now?", "options": ["Grade 1 pneumonitis; continue pembrolizumab with close monitoring only", "Grade 2 pneumonitis; hold pembrolizumab and start prednisone 0.5 mg/kg/day", "Grade 2 pneumonitis; hold pembrolizumab and start prednisone 1-2 mg/kg/day", "Grade 3 pneumonitis; permanently discontinue pembrolizumab and give IV methylprednisolone 1-2 mg/kg/day", "Grade 3 pneumonitis; permanently discontinue pembrolizumab and give infliximab immediately without steroids"], "answer": "C", "answer_index": 2, "explanation": "He has symptomatic but non-life-threatening immune-related pneumonitis (dyspnea, new infiltrates, no severe hypoxia), corresponding to grade 2; standard management is to hold the checkpoint inhibitor and start systemic steroids at 1-2 mg/kg/day with a prolonged taper. Grade 3 would involve severe symptoms or oxygen requirement; lower steroid doses or continuation of pembrolizumab are inadequate, and infliximab is reserved for steroid-refractory cases, not first-line.", "generator_model": "gpt-5.1-2025-11-13", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: 66-year-old on pembrolizumab with 4 days of worsening exertional dyspnea and dry cough, afebrile, new bilateral patchy ground-glass/reticular opacities with subpleural sparing, no infection, normal BNP and no cardiac ischemia, no other new drugs, O2 sat 90% on room air. This is consistent with immune-related pneumonitis that is symptomatic but not clearly life-threatening (no ICU-level respiratory failure described), meeting CTCAE grade 2 criteria (symptomatic, limiting instrumental ADLs, no severe hypoxia or continuous oxygen documented).\\nThe keyed answer (C) correctly identifies this as grade 2 pneumonitis and recommends holding pembrolizumab with systemic corticosteroids at 1–2 mg/kg/day, which matches current checkpoint inhibitor toxicity guidelines. Option A is incorrect because symptomatic disease is not grade 1 and therapy should not be continued. Option B underdoses steroids for grade 2. Options D and E overtreat as grade 3 and would inappropriately mandate permanent discontinuation or biologic therapy; infliximab is second-line for steroid-refractory cases. No major medical inaccuracies or internal contradictions are present.\\nMinimal fix: Explicitly state that he requires only intermittent/low-flow oxygen, not ICU-level support, to solidify grade 2 vs 3 classification.\\n\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: 66-year-old on pembrolizumab with 4 days of worsening exertional dyspnea and dry cough, afebrile, new bilateral patchy ground-glass/reticular opacities with subpleural sparing, no infection, normal BNP and no cardiac ischemia, no other new drugs, O2 sat 90% on room air. This is consistent with immune-related pneumonitis that is symptomatic but not clearly life-threatening (no ICU-level respiratory failure described), meeting CTCAE grade 2 criteria (symptomatic, limiting instrumental ADLs, no severe hypoxia or continuous oxygen documented).\nThe keyed answer (C) correctly identifies this as grade 2 pneumonitis and recommends holding pembrolizumab with systemic corticosteroids at 1–2 mg/kg/day, which matches current checkpoint inhibitor toxicity guidelines. Option A is incorrect because symptomatic disease is not grade 1 and therapy should not be continued. Option B underdoses steroids for grade 2. Options D and E overtreat as grade 3 and would inappropriately mandate permanent discontinuation or biologic therapy; infliximab is second-line for steroid-refractory cases. No major medical inaccuracies or internal contradictions are present.\nMinimal fix: Explicitly state that he requires only intermittent/low-flow oxygen, not ICU-level support, to solidify grade 2 vs 3 classification.\n", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125-007", "question": "A 9-year-old girl presents with 2 weeks of progressive headache, morning vomiting, and decline in school performance. Exam reveals papilledema, dysmetria, and truncal ataxia. MRI brain shows an enhancing midline posterior fossa mass infiltrating the cerebellar vermis and roof of the fourth ventricle, with obstructive hydrocephalus. After CSF diversion and near-total resection, histology shows small round blue cells with Homer-Wright rosettes. Molecular profiling reveals WNT-activated medulloblastoma, CTNNB1 mutation, and monosomy 6; no metastatic disease on staging. Which adjuvant treatment strategy is most appropriate?", "options": ["Craniospinal irradiation at standard dose plus multi-agent chemotherapy (high-risk protocol)", "Focal posterior fossa irradiation only plus maintenance oral temozolomide", "Reduced-dose craniospinal irradiation with posterior fossa boost plus chemotherapy (standard-risk protocol)", "Observation only after gross total resection due to favorable WNT subtype", "High-dose chemotherapy with autologous stem cell rescue, without craniospinal irradiation"], "answer": "C", "answer_index": 2, "explanation": "WNT-activated medulloblastoma in a child with non-metastatic disease and near-total resection is standard-risk; current practice uses reduced-dose craniospinal irradiation with posterior fossa boost plus multi-agent chemotherapy to maintain excellent survival while reducing late toxicity. Standard-dose/high-risk protocols are unnecessary; focal RT alone or observation is inadequate due to CSF dissemination risk; high-dose chemo without CSI is investigational and not standard in this scenario.", "generator_model": "gpt-5.1-2025-11-13", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: 9-year-old with classic medulloblastoma features (posterior fossa midline mass, small round blue cells, Homer-Wright rosettes) and molecular profile showing WNT-activated subtype (CTNNB1 mutation, monosomy 6), non-metastatic, after near-total resection. This defines standard-risk WNT medulloblastoma. Standard contemporary management for standard-risk medulloblastoma in school-aged children is reduced-dose craniospinal irradiation (CSI) with posterior fossa boost plus multi-agent chemotherapy to balance cure rates and late toxicity.\\nChoice C explicitly describes reduced-dose CSI with posterior fossa boost plus chemotherapy (standard-risk protocol), matching current guidelines. A (standard-dose CSI/high-risk protocol) is excessive toxicity for standard-risk WNT disease. B (focal RT only + temozolomide) under-treats CSF dissemination risk. D (observation alone) is clearly inappropriate for medulloblastoma, even with favorable WNT subtype. E (high-dose chemotherapy with stem cell rescue, no CSI) is investigational and not standard for this setting.\\nNo logical contradictions or underspecification; staging information (no metastases) and extent of resection are provided. \\nMinimal fix: Clarify chemotherapy as “multi-agent systemic chemotherapy per standard-risk medulloblastoma protocol” in Choice C for maximal precision.\\n\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: 9-year-old with classic medulloblastoma features (posterior fossa midline mass, small round blue cells, Homer-Wright rosettes) and molecular profile showing WNT-activated subtype (CTNNB1 mutation, monosomy 6), non-metastatic, after near-total resection. This defines standard-risk WNT medulloblastoma. Standard contemporary management for standard-risk medulloblastoma in school-aged children is reduced-dose craniospinal irradiation (CSI) with posterior fossa boost plus multi-agent chemotherapy to balance cure rates and late toxicity.\nChoice C explicitly describes reduced-dose CSI with posterior fossa boost plus chemotherapy (standard-risk protocol), matching current guidelines. A (standard-dose CSI/high-risk protocol) is excessive toxicity for standard-risk WNT disease. B (focal RT only + temozolomide) under-treats CSF dissemination risk. D (observation alone) is clearly inappropriate for medulloblastoma, even with favorable WNT subtype. E (high-dose chemotherapy with stem cell rescue, no CSI) is investigational and not standard for this setting.\nNo logical contradictions or underspecification; staging information (no metastases) and extent of resection are provided. \nMinimal fix: Clarify chemotherapy as “multi-agent systemic chemotherapy per standard-risk medulloblastoma protocol” in Choice C for maximal precision.\n", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125-008", "question": "A 71-year-old woman with hypertension and atrial fibrillation on rivaroxaban is admitted with sudden onset aphasia and right hemiplegia. CT head is negative for hemorrhage; CTA shows left M1 occlusion. Last rivaroxaban dose was 3 hours ago. Labs: creatinine 0.9 mg/dL, normal platelets, INR 1.2, anti-factor Xa level (rivaroxaban-calibrated) 170 ng/mL. She arrives 70 minutes after symptom onset. You are in a center with neurointerventional capability and access to andexanet alfa and 4-factor PCC. What is the best acute reperfusion strategy?", "options": ["Administer IV alteplase followed by mechanical thrombectomy", "Administer andexanet alfa to reverse rivaroxaban, then give IV alteplase", "Proceed directly to mechanical thrombectomy without IV thrombolysis", "Give 4-factor PCC then IV alteplase to offset rivaroxaban effect", "Defer reperfusion therapy and manage with permissive hypertension alone"], "answer": "C", "answer_index": 2, "explanation": "Recent rivaroxaban ingestion with high anti-factor Xa level is a contraindication to IV alteplase, and reversal with andexanet or PCC before tPA is not recommended due to uncertain safety and lack of evidence. In patients with large-vessel occlusion on DOACs, direct mechanical thrombectomy is the preferred reperfusion strategy. Withholding reperfusion altogether is inappropriate given eligibility for thrombectomy.", "generator_model": "gpt-5.1-2025-11-13", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: 71-year-old with acute disabling ischemic stroke (aphasia, right hemiplegia) arriving within 70 minutes; CT negative for hemorrhage; CTA shows left M1 large-vessel occlusion; on rivaroxaban with last dose 3 hours ago and high anti–factor Xa level (170 ng/mL); normal renal function; center has thrombectomy and reversal agents.\\nThese findings indicate acute LVO stroke in a patient with very recent DOAC ingestion and clearly therapeutic rivaroxaban level. Current AHA/ASA and ESO guidance consider recent DOAC use with therapeutic levels a contraindication to IV alteplase outside trials. Reversal with andexanet alfa or 4F-PCC prior to tPA is not guideline-supported and lacks safety/efficacy data. However, recent trials and guidelines support mechanical thrombectomy for eligible LVO strokes irrespective of recent DOAC use. Thus, proceeding directly to mechanical thrombectomy (C) is the single best, evidence-consistent choice. Options A, B, and D all involve IV alteplase despite recent DOAC use; E inappropriately withholds reperfusion despite thrombectomy eligibility. \\nMinimal fix: Option C could be reworded to “Proceed directly to emergent mechanical thrombectomy without IV thrombolysis” to emphasize urgency but does not affect correctness.\\n\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: 71-year-old with acute disabling ischemic stroke (aphasia, right hemiplegia) arriving within 70 minutes; CT negative for hemorrhage; CTA shows left M1 large-vessel occlusion; on rivaroxaban with last dose 3 hours ago and high anti–factor Xa level (170 ng/mL); normal renal function; center has thrombectomy and reversal agents.\nThese findings indicate acute LVO stroke in a patient with very recent DOAC ingestion and clearly therapeutic rivaroxaban level. Current AHA/ASA and ESO guidance consider recent DOAC use with therapeutic levels a contraindication to IV alteplase outside trials. Reversal with andexanet alfa or 4F-PCC prior to tPA is not guideline-supported and lacks safety/efficacy data. However, recent trials and guidelines support mechanical thrombectomy for eligible LVO strokes irrespective of recent DOAC use. Thus, proceeding directly to mechanical thrombectomy (C) is the single best, evidence-consistent choice. Options A, B, and D all involve IV alteplase despite recent DOAC use; E inappropriately withholds reperfusion despite thrombectomy eligibility. \nMinimal fix: Option C could be reworded to “Proceed directly to emergent mechanical thrombectomy without IV thrombolysis” to emphasize urgency but does not affect correctness.\n", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125-009", "question": "A 22-year-old man with sickle cell disease (HbSS) presents with high fever, cough, and pleuritic chest pain. CXR shows new multilobar infiltrates; oxygen saturation is 93% on 2 L/min nasal cannula. Labs: Hgb 7.2 g/dL (baseline 8.5), WBC 18,000/µL, platelets 310,000/µL, reticulocyte count 12%. He is diagnosed with acute chest syndrome and started on broad-spectrum antibiotics, incentive spirometry, and simple transfusion to Hgb 9.5 g/dL. Over 24 hours, oxygen requirement increases to 8 L/min with SpO2 90%, and CXR shows progression to near-complete bilateral airspace opacification. Hgb is now 10.3 g/dL, and he is tachypneic but not yet intubated. Which is the most appropriate next step?", "options": ["Increase simple transfusions to target Hgb 12 g/dL for better oxygen-carrying capacity", "Initiate exchange transfusion targeting HbS <30%", "Start high-dose corticosteroids to reduce pulmonary inflammation", "Add therapeutic anticoagulation for presumed pulmonary embolism", "Intubate and initiate low tidal-volume ventilation, deferring transfusion changes"], "answer": "B", "answer_index": 1, "explanation": "Worsening hypoxemia, radiographic progression, and clinical deterioration despite initial simple transfusion indicate severe acute chest syndrome, for which exchange transfusion to rapidly lower HbS (<30%) is recommended. Further simple transfusion risks hyperviscosity; steroids are controversial and may increase rebound pain; empiric anticoagulation is not first-line without PE evidence; ventilation may be needed but does not replace disease-modifying exchange.", "generator_model": "gpt-5.1-2025-11-13", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Adult with HbSS, acute chest syndrome diagnosed; already on appropriate initial therapy (broad-spectrum antibiotics, incentive spirometry, simple transfusion to Hgb ~9.5). Over 24 hours he has clear clinical deterioration: rising O2 requirement (now 8 L/min with SpO2 90%), radiographic progression to near-complete bilateral opacification, and Hgb now >10 g/dL. These changes define severe acute chest syndrome despite simple transfusion and raise concern for worsening vaso-occlusion and hyperviscosity if further simple transfusions are given.\\nB (exchange transfusion targeting HbS <30%) is guideline-consistent for severe or progressive acute chest syndrome with increasing O2 needs and extensive infiltrates. A is inappropriate due to hyperviscosity risk at Hgb 10.3. C: high-dose steroids in acute chest are controversial and not first-line, especially without prior exchange. D: empiric anticoagulation without PE evidence is not standard. E: escalating respiratory support may soon be needed but does not address the underlying sickling and is not an alternative to exchange.\\nMain medical accuracy issues: None significant; rationale is current and standard.\\nMinimal fix: Explicitly note that PE workup is negative to further weaken D, though not strictly necessary.\\n\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Adult with HbSS, acute chest syndrome diagnosed; already on appropriate initial therapy (broad-spectrum antibiotics, incentive spirometry, simple transfusion to Hgb ~9.5). Over 24 hours he has clear clinical deterioration: rising O2 requirement (now 8 L/min with SpO2 90%), radiographic progression to near-complete bilateral opacification, and Hgb now >10 g/dL. These changes define severe acute chest syndrome despite simple transfusion and raise concern for worsening vaso-occlusion and hyperviscosity if further simple transfusions are given.\nB (exchange transfusion targeting HbS <30%) is guideline-consistent for severe or progressive acute chest syndrome with increasing O2 needs and extensive infiltrates. A is inappropriate due to hyperviscosity risk at Hgb 10.3. C: high-dose steroids in acute chest are controversial and not first-line, especially without prior exchange. D: empiric anticoagulation without PE evidence is not standard. E: escalating respiratory support may soon be needed but does not address the underlying sickling and is not an alternative to exchange.\nMain medical accuracy issues: None significant; rationale is current and standard.\nMinimal fix: Explicitly note that PE workup is negative to further weaken D, though not strictly necessary.\n", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125-010", "question": "A 58-year-old man with alcohol-related cirrhosis and portal hypertension is admitted with confusion and generalized tonic-clonic seizures. He has been on valproic acid for epilepsy for 5 years without prior complications. Medications include lactulose and spironolactone. Exam: asterixis, disorientation, jaundice, and mild ascites. Labs: Na 130 mmol/L, K 4.2 mmol/L, BUN 10 mg/dL, creatinine 0.7 mg/dL, AST 65 U/L, ALT 40 U/L, total bilirubin 3.8 mg/dL, INR 1.7, ammonia 96 µmol/L. Serum valproate level is therapeutic, but free valproate level is supratherapeutic; serum carnitine is low, and EEG shows triphasic waves without epileptiform activity. Which is the most appropriate antiseizure management strategy?", "options": ["Continue valproic acid but lower the dose and optimize lactulose therapy", "Discontinue valproic acid and start levetiracetam with IV L-carnitine supplementation", "Switch valproic acid to phenytoin with aggressive albumin replacement", "Add topiramate to valproic acid to improve seizure control", "Continue valproic acid and start rifaximin to reduce ammonia"], "answer": "B", "answer_index": 1, "explanation": "He has cirrhosis with hyperammonemic encephalopathy and high free valproate, consistent with valproate-induced hyperammonemic encephalopathy exacerbated by liver disease and carnitine deficiency; the best approach is to stop valproate, use a non-hepatically metabolized agent such as levetiracetam, and give IV L-carnitine. Dose reduction or adjuncts (lactulose, rifaximin) without discontinuing valproate will not adequately address toxicity; phenytoin is highly protein-bound and hepatically metabolized, and adding topiramate may worsen hyperammonemia.", "generator_model": "gpt-5.1-2025-11-13", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Known alcohol-related cirrhosis with portal hypertension; encephalopathy (confusion, asterixis, triphasic waves) and seizures; therapeutic total but supratherapeutic free valproate level; low carnitine; elevated ammonia; normal renal function. These support valproate-associated hyperammonemic encephalopathy, worsened by cirrhosis and carnitine deficiency despite a “therapeutic” total level.\\nOption B is best: stopping valproate removes the offending agent; levetiracetam has minimal hepatic metabolism and few interactions, appropriate in cirrhosis; IV L‑carnitine is standard supportive therapy for valproate toxicity/hyperammonemia. \\nOther options: A/E both continue valproate and only address ammonia via lactulose/rifaximin—do not treat the primary drug toxicity and risk ongoing injury. C: phenytoin is hepatically metabolized and highly protein bound; in cirrhotics with low albumin this creates similar free‑drug toxicity issues. D: adding topiramate to valproate can further increase risk of hyperammonemia and cognitive adverse effects.\\nNo major logical or medical inconsistencies; discrimination among options is clear and aligned with contemporary practice.\\nMinimal fix: Explicitly state that albumin is low to further justify concern about free valproate and to clarify why phenytoin is a poor alternative.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Known alcohol-related cirrhosis with portal hypertension; encephalopathy (confusion, asterixis, triphasic waves) and seizures; therapeutic total but supratherapeutic free valproate level; low carnitine; elevated ammonia; normal renal function. These support valproate-associated hyperammonemic encephalopathy, worsened by cirrhosis and carnitine deficiency despite a “therapeutic” total level.\nOption B is best: stopping valproate removes the offending agent; levetiracetam has minimal hepatic metabolism and few interactions, appropriate in cirrhosis; IV L‑carnitine is standard supportive therapy for valproate toxicity/hyperammonemia. \nOther options: A/E both continue valproate and only address ammonia via lactulose/rifaximin—do not treat the primary drug toxicity and risk ongoing injury. C: phenytoin is hepatically metabolized and highly protein bound; in cirrhotics with low albumin this creates similar free‑drug toxicity issues. D: adding topiramate to valproate can further increase risk of hyperammonemia and cognitive adverse effects.\nNo major logical or medical inconsistencies; discrimination among options is clear and aligned with contemporary practice.\nMinimal fix: Explicitly state that albumin is low to further justify concern about free valproate and to clarify why phenytoin is a poor alternative.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}]